car t-cell therapy...goals: pi-rnomlal: is x liln: crpoprxipttatc for goal fibrinogen ico nou consul...
TRANSCRIPT
-
CAR T-cell therapy
-
Chimeric antigen receptors (CARs)
-
CARs
-
CAR T-cell toxicities
-
Neurological toxicities
-
Toxicity grading system
-
Supportive care
-
Tocilizumab
-
Indications for corticosteroids
-
Toxicity factors
-
Risk factors
-
Infection risk
-
Severe toxicity
-
NIH specific thresholds
-
B cell maturation antigen
-
Multiple myeloma
-
Multiple myeloma
-
Protocol design
-
B-cell maturation antigen
-
T cell engineering
-
Patient characteristics
-
Multiple myeloma reduction
-
Patient 14
-
Response summary
-
Anti-BCMA CAR T cells
-
Anti-BCMA CAR T-cell summary
-
Study CRB401
-
Bb2121 responses
-
Progression-free survival
-
Room for improvement
-
CARs with heavy chain only
-
Clinical trail
-
Demographics
-
Summary
-
Relapse
-
Future plans
-
Acknowledgements